CAS 1354690-24-6

Leniolisib

CAS : 1354690-24-6

Formule : C₂₁H₂₅F₃N₆O₂

Degré de pureté : 99%

Couleur et forme : Solid

Masse moléculaire : 450.4574

Ref: IN-DA01EN5I

(S)-1-(3-((6-(6-Methoxy-5-(Trifluoromethyl)Pyridin-3-Yl)-5,6,7,8-Tetrahydropyrido[4,3-D]Pyrimidin-4-Yl)Amino)Pyrrolidin-1-Yl)Propan-1-One

CAS : 1354690-24-6

(S)-1-(3-((6-(6-Methoxy-5-(Trifluoromethyl)Pyridin-3-Yl)-5,6,7,8-Tetrahydropyrido[4,3-D]Pyrimidin-4-Yl)Amino)Pyrrolidin-1-Yl)Propan-1-One

Degré de pureté : 99%

Masse moléculaire : 450.46g/mol

Ref: 54-PC108439

Leniolisib

CAS : 1354690-24-6

Leniolisib

Degré de pureté : ≥98%

Masse moléculaire : 450.46g/mol

Ref: 54-BUP04192

Leniolisib

CAS : 1354690-24-6

Leniolisib (CDZ173) (CDZ173) is a potent and selective PI3Kδ inhibitor (IC50: 11 nM).

Formule : C₂₁H₂₅F₃N₆O₂

Degré de pureté : 99.88%

Couleur et forme : Solid

Masse moléculaire : 450.46

Ref: TM-T5166

Leniolisib

CAS : 1354690-24-6

Leniolisib is a small molecule that inhibits the lipid kinase activity of the enzyme phosphatidylinositol 3-kinase (PI3K). This drug has been shown to have an anti-inflammatory effect in vitro, which may be due to its ability to inhibit the secretion of inflammatory mediators and cytokines from activated macrophages. Leniolisib also has been shown to have immunosuppressive properties, which may be due to its ability to induce apoptosis in lymphocytes. This drug also has been shown to suppress the growth of tumor cells in vitro by inhibiting cell cycle progression at G1 phase and inducing senescence. This drug may have potential as a therapeutic for autoimmune diseases such as rheumatoid arthritis and multiple sclerosis.

Formule : C₂₁H₂₅F₃N₆O₂

Degré de pureté : Min. 95%

Masse moléculaire : 450.46 g/mol

Ref: 3D-EEC69024